{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T18:20:32Z","timestamp":1788373232160,"version":"build-2803163510"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T00:00:00Z","timestamp":1788307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T00:00:00Z","timestamp":1788307200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Antimicrob Resist"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Pritelivir, a novel helicase-primase inhibitor, has successfully completed a global Phase 3 trial for refractory herpes simplex virus (HSV) infections in immunocompromised patients. This case report is the first clinical use of pritelivir in Herpes simplex encephalitis (HSE). An allogeneic hematopoietic cell transplant recipient developed HSE and was treated with acyclovir. After 1.5 months, while still on valacyclovir prophylaxis, HSE relapsed, confirmed by Magnetic Resonance Imaging (MRI) and HSV1 DNA detection in cerebrospinal fluid (CSF). Following transient response to acyclovir and foscarnet, combined pritelivir\/acyclovir treatment was initiated in this comatose patient with cerebral edema and necrosis. Clinical improvement occurred with increased alertness and motor activity, enabling discharge to rehabilitation. MRI showed no further progression, and CSF HSV DNA load became undetectable. No relevant adverse effects were observed. Pritelivir plasma and CSF concentrations exceeded the 50% effective concentration for HSV1. This case highlights the potential of pritelivir for treating HSE.<\/jats:p>","DOI":"10.1038\/s44259-026-00262-z","type":"journal-article","created":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T17:43:26Z","timestamp":1788371006000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Treatment of Herpes simplex encephalitis with the helicase-primase inhibitor pritelivir in an immunocompromised patient"],"prefix":"10.1038","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9597-6142","authenticated-orcid":false,"given":"Catherina","family":"Lueck","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Rautenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Birkmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"Bonsmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Marini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie","family":"Sumner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Schroeder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Voigt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,2]]},"reference":[{"key":"262_CR1","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1086\/521262","volume":"45","author":"A Hjalmarsson","year":"2007","unstructured":"Hjalmarsson, A., Blomqvist, P. & Skoldenberg, B. Herpes simplex encephalitis in Sweden, 1990-2001: incidence, morbidity, and mortality. Clin. Infect. Dis. 45, 875\u2013880, https:\/\/doi.org\/10.1086\/521262 (2007).","journal-title":"Clin. Infect. Dis."},{"key":"262_CR2","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1086\/341405","volume":"35","author":"F Raschilas","year":"2002","unstructured":"Raschilas, F. et al. Outcome of and prognostic factors for herpes simplex encephalitis in adult patients: results of a multicenter study. Clin. Infect. Dis. 35, 254\u2013260, https:\/\/doi.org\/10.1086\/341405 (2002).","journal-title":"Clin. Infect. Dis."},{"key":"262_CR3","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1097\/WCO.0b013e328346be6f","volume":"24","author":"I Steiner","year":"2011","unstructured":"Steiner, I. Herpes simplex virus encephalitis: new infection or reactivation?. Curr. Opin. Neurol. 24, 268\u2013274, https:\/\/doi.org\/10.1097\/WCO.0b013e328346be6f (2011).","journal-title":"Curr. Opin. Neurol."},{"key":"262_CR4","doi-asserted-by":"publisher","first-page":"e77805","DOI":"10.1371\/journal.pone.0077805","volume":"8","author":"M Wu","year":"2013","unstructured":"Wu, M. et al. Herpesvirus-associated central nervous system diseases after allogeneic hematopoietic stem cell transplantation. PLoS One 8, e77805, https:\/\/doi.org\/10.1371\/journal.pone.0077805 (2013).","journal-title":"PLoS One"},{"key":"262_CR5","doi-asserted-by":"publisher","first-page":"142","DOI":"10.3324\/haematol.2010.029876","volume":"96","author":"M Schmidt-Hieber","year":"2011","unstructured":"Schmidt-Hieber, M. et al. Viral encephalitis after allogeneic stem cell transplantation: a rare complication with distinct characteristics of different causative agents. Haematologica 96, 142\u2013149, https:\/\/doi.org\/10.3324\/haematol.2010.029876 (2011).","journal-title":"Haematologica"},{"key":"262_CR6","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1128\/AAC.37.5.1010","volume":"37","author":"UR Hengge","year":"1993","unstructured":"Hengge, U. R., Brockmeyer, N. H., Malessa, R., Ravens, U. & Goos, M. Foscarnet penetrates the blood-brain barrier: rationale for therapy of cytomegalovirus encephalitis. Antimicrob. Agents Chemother. 37, 1010\u20131014, https:\/\/doi.org\/10.1128\/AAC.37.5.1010 (1993).","journal-title":"Antimicrob. Agents Chemother."},{"key":"262_CR7","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.1128\/AAC.37.9.1777","volume":"37","author":"F Raffi","year":"1993","unstructured":"Raffi, F., Taburet, A. M., Ghaleh, B., Huart, A. & Singlas, E. Penetration of foscarnet into cerebrospinal fluid of AIDS patients. Antimicrob. Agents Chemother. 37, 1777\u20131780, https:\/\/doi.org\/10.1128\/AAC.37.9.1777 (1993).","journal-title":"Antimicrob. Agents Chemother."},{"key":"262_CR8","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1016\/j.cmi.2025.01.033","volume":"31","author":"T Shafat","year":"2025","unstructured":"Shafat, T., Ariza-Heredia, E. J., Daher, M. & Chemaly, R. F. How we diagnose and manage refractory and resistant herpes simplex virus mucocutaneous infection after haematopoietic cell transplantation. Clin. Microbiol Infect. 31, 761\u2013772, https:\/\/doi.org\/10.1016\/j.cmi.2025.01.033 (2025).","journal-title":"Clin. Microbiol Infect."},{"key":"262_CR9","doi-asserted-by":"publisher","first-page":"13614","DOI":"10.1021\/acs.jmedchem.2c00668","volume":"65","author":"A Birkmann","year":"2022","unstructured":"Birkmann, A. et al. Discovery, chemistry, and preclinical development of pritelivir, a novel treatment option for acyclovir-resistant herpes simplex virus infections. J. Med Chem. 65, 13614\u201313628, https:\/\/doi.org\/10.1021\/acs.jmedchem.2c00668 (2022).","journal-title":"J. Med Chem."},{"key":"262_CR10","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1093\/cid\/ciae638","volume":"81","author":"RF Chemaly","year":"2025","unstructured":"Chemaly, R. F. et al. Refractory and resistant herpes simplex virus mucocutaneous infections in immunocompromised patients: literature review and proposed definitions for use in clinical trials. Clin. Infect. Dis. 81, 593\u2013601, https:\/\/doi.org\/10.1093\/cid\/ciae638 (2025).","journal-title":"Clin. Infect. Dis."},{"key":"262_CR11","doi-asserted-by":"publisher","first-page":"S18","DOI":"10.1016\/j.jtct.2026.02.038","volume":"32","author":"GA Papanicolaou","year":"2026","unstructured":"Papanicolaou, G. A. et al. Pritelivir demonstrated superior efficacy compared to investigator\u2019s choice treatment for refractory herpes simplex virus infections in immunocompromised patients: PRIOH-1, phase 3 safety and efficacy. Transplant. Cell. Ther. 32, S18\u2013S19, https:\/\/doi.org\/10.1016\/j.jtct.2026.02.038 (2026).","journal-title":"Transplant. Cell. Ther."},{"key":"262_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.antiviral.2017.11.002","volume":"149","author":"DC Quenelle","year":"2018","unstructured":"Quenelle, D. C. et al. Efficacy of pritelivir and acyclovir in the treatment of herpes simplex virus infections in a mouse model of herpes simplex encephalitis. Antivir. Res 149, 1\u20136, https:\/\/doi.org\/10.1016\/j.antiviral.2017.11.002 (2018).","journal-title":"Antivir. Res"},{"key":"262_CR13","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.antiviral.2013.08.024","volume":"100","author":"HJ Field","year":"2013","unstructured":"Field, H. J. et al. Baseline sensitivity of HSV-1 and HSV-2 clinical isolates and defined acyclovir-resistant strains to the helicase-primase inhibitor pritelivir. Antivir. Res 100, 297\u2013299, https:\/\/doi.org\/10.1016\/j.antiviral.2013.08.024 (2013).","journal-title":"Antivir. Res"}],"container-title":["npj Antimicrobials and Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s44259-026-00262-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s44259-026-00262-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s44259-026-00262-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T18:07:28Z","timestamp":1788372448000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s44259-026-00262-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,2]]},"references-count":13,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["262"],"URL":"https:\/\/doi.org\/10.1038\/s44259-026-00262-z","relation":{},"ISSN":["2731-8745"],"issn-type":[{"value":"2731-8745","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,2]]},"assertion":[{"value":"15 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"C.L., T.S., C.R. and S.V. declare no Competing Financial or Non-Financial Interests. A.B., S.B., A.M., and M.S. declare no Competing Non-Financial Interests but the following Competing Financial Interests: They are employees of AiCuris Anti-Infective Cures AG, the company that develops pritelivir and provided the drug in an Early Access Program.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"56"}}